KRAS pathway expression changes in pancreatic cancer models by conventional and experimental taxanes

The KRAS signalling pathway is pivotal for pancreatic ductal adenocarcinoma (PDAC) development. After the failure of most conventional cytotoxic and targeted therapeutics tested so far, the combination of taxane nab-paclitaxel (Abraxane) with gemcitabine recently demonstrated promising improvements...

全面介紹

Na minha lista:
書目詳細資料
發表在:Mutagenesis
Main Authors: Oliverius, M, Flasarova, D, Mohelnikova-Duchonova, B, Ehrlichova, M, Hlavac, V, Kocik, M, Strouhal, O, Dvorak, P, Ojima, I, Soucek, P
格式: Artigo
語言:Inglês
出版: Oxford University Press 2019
主題:
Special Topic
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6923165/
https://ncbi.nlm.nih.gov/pubmed/31375828
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/mutage/gez021
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍